vs

Side-by-side financial comparison of KRONOS WORLDWIDE INC (KRO) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $418.3M, roughly 1.2× KRONOS WORLDWIDE INC). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -19.8%, a 26.6% gap on every dollar of revenue. On growth, KRONOS WORLDWIDE INC posted the faster year-over-year revenue change (-1.1% vs -1.7%). Over the past eight quarters, Pediatrix Medical Group, Inc.'s revenue compounded faster (-0.1% CAGR vs -6.5%).

Kronos Incorporated was an American multinational workforce management and human capital management cloud provider headquartered in Lowell, Massachusetts, United States, which employed more than 6,000 people worldwide.

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

KRO vs MD — Head-to-Head

Bigger by revenue
MD
MD
1.2× larger
MD
$493.8M
$418.3M
KRO
Growing faster (revenue YoY)
KRO
KRO
+0.6% gap
KRO
-1.1%
-1.7%
MD
Higher net margin
MD
MD
26.6% more per $
MD
6.8%
-19.8%
KRO
Faster 2-yr revenue CAGR
MD
MD
Annualised
MD
-0.1%
-6.5%
KRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KRO
KRO
MD
MD
Revenue
$418.3M
$493.8M
Net Profit
$-82.8M
$33.7M
Gross Margin
-0.9%
Operating Margin
-15.1%
9.9%
Net Margin
-19.8%
6.8%
Revenue YoY
-1.1%
-1.7%
Net Profit YoY
-527.3%
10.5%
EPS (diluted)
$-0.72
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KRO
KRO
MD
MD
Q4 25
$418.3M
$493.8M
Q3 25
$456.9M
$492.9M
Q2 25
$494.4M
$468.8M
Q1 25
$489.8M
$458.4M
Q4 24
$423.1M
$502.4M
Q3 24
$484.7M
$511.2M
Q2 24
$500.5M
$504.3M
Q1 24
$478.8M
$495.1M
Net Profit
KRO
KRO
MD
MD
Q4 25
$-82.8M
$33.7M
Q3 25
$-37.0M
$71.7M
Q2 25
$-9.2M
$39.3M
Q1 25
$18.1M
$20.7M
Q4 24
$-13.2M
$30.5M
Q3 24
$71.8M
$19.4M
Q2 24
$19.5M
$-153.0M
Q1 24
$8.1M
$4.0M
Gross Margin
KRO
KRO
MD
MD
Q4 25
-0.9%
Q3 25
10.3%
Q2 25
12.7%
Q1 25
21.8%
Q4 24
20.4%
Q3 24
20.9%
Q2 24
20.0%
Q1 24
14.9%
Operating Margin
KRO
KRO
MD
MD
Q4 25
-15.1%
9.9%
Q3 25
-4.2%
13.8%
Q2 25
1.5%
12.8%
Q1 25
7.8%
7.0%
Q4 24
6.8%
7.8%
Q3 24
8.0%
6.6%
Q2 24
7.2%
-31.3%
Q1 24
4.1%
3.2%
Net Margin
KRO
KRO
MD
MD
Q4 25
-19.8%
6.8%
Q3 25
-8.1%
14.5%
Q2 25
-1.9%
8.4%
Q1 25
3.7%
4.5%
Q4 24
-3.1%
6.1%
Q3 24
14.8%
3.8%
Q2 24
3.9%
-30.3%
Q1 24
1.7%
0.8%
EPS (diluted)
KRO
KRO
MD
MD
Q4 25
$-0.72
$0.40
Q3 25
$-0.32
$0.84
Q2 25
$-0.08
$0.46
Q1 25
$0.16
$0.24
Q4 24
$-0.11
$0.37
Q3 24
$0.62
$0.23
Q2 24
$0.17
$-1.84
Q1 24
$0.07
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KRO
KRO
MD
MD
Cash + ST InvestmentsLiquidity on hand
$33.2M
$375.2M
Total DebtLower is stronger
$557.4M
$570.5M
Stockholders' EquityBook value
$751.1M
$865.9M
Total Assets
$1.8B
$2.2B
Debt / EquityLower = less leverage
0.74×
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KRO
KRO
MD
MD
Q4 25
$33.2M
$375.2M
Q3 25
$27.7M
$340.1M
Q2 25
$18.9M
$224.7M
Q1 25
$20.5M
$99.0M
Q4 24
$106.7M
$229.9M
Q3 24
$94.8M
$103.8M
Q2 24
$133.8M
$19.4M
Q1 24
$120.7M
$8.0M
Total Debt
KRO
KRO
MD
MD
Q4 25
$557.4M
$570.5M
Q3 25
$626.2M
$577.2M
Q2 25
$589.3M
$583.9M
Q1 25
$557.2M
$590.5M
Q4 24
$507.4M
$597.1M
Q3 24
$554.3M
Q2 24
$423.7M
Q1 24
$426.9M
Stockholders' Equity
KRO
KRO
MD
MD
Q4 25
$751.1M
$865.9M
Q3 25
$804.7M
$890.7M
Q2 25
$846.8M
$833.8M
Q1 25
$847.0M
$789.2M
Q4 24
$817.0M
$764.9M
Q3 24
$847.4M
$732.5M
Q2 24
$774.6M
$706.5M
Q1 24
$774.4M
$856.2M
Total Assets
KRO
KRO
MD
MD
Q4 25
$1.8B
$2.2B
Q3 25
$1.9B
$2.2B
Q2 25
$1.9B
$2.1B
Q1 25
$1.9B
$2.0B
Q4 24
$1.9B
$2.2B
Q3 24
$1.9B
$2.1B
Q2 24
$1.7B
$2.0B
Q1 24
$1.7B
$2.2B
Debt / Equity
KRO
KRO
MD
MD
Q4 25
0.74×
0.66×
Q3 25
0.78×
0.65×
Q2 25
0.70×
0.70×
Q1 25
0.66×
0.75×
Q4 24
0.62×
0.78×
Q3 24
0.65×
Q2 24
0.55×
Q1 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KRO
KRO
MD
MD
Operating Cash FlowLast quarter
$92.1M
$114.1M
Free Cash FlowOCF − Capex
$81.9M
FCF MarginFCF / Revenue
19.6%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
3.39×
TTM Free Cash FlowTrailing 4 quarters
$-40.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KRO
KRO
MD
MD
Q4 25
$92.1M
$114.1M
Q3 25
$-7.9M
$137.3M
Q2 25
$20.7M
$137.2M
Q1 25
$-102.4M
$-117.5M
Q4 24
$49.3M
$133.0M
Q3 24
$28.3M
$91.8M
Q2 24
$38.2M
$107.0M
Q1 24
$-43.3M
$-125.2M
Free Cash Flow
KRO
KRO
MD
MD
Q4 25
$81.9M
Q3 25
$-17.4M
Q2 25
$9.5M
Q1 25
$-114.4M
Q4 24
$37.0M
Q3 24
$19.2M
Q2 24
$34.8M
Q1 24
$-48.0M
FCF Margin
KRO
KRO
MD
MD
Q4 25
19.6%
Q3 25
-3.8%
Q2 25
1.9%
Q1 25
-23.4%
Q4 24
8.7%
Q3 24
4.0%
Q2 24
7.0%
Q1 24
-10.0%
Capex Intensity
KRO
KRO
MD
MD
Q4 25
2.4%
Q3 25
2.1%
Q2 25
2.3%
Q1 25
2.4%
Q4 24
2.9%
Q3 24
1.9%
Q2 24
0.7%
Q1 24
1.0%
Cash Conversion
KRO
KRO
MD
MD
Q4 25
3.39×
Q3 25
1.91×
Q2 25
3.49×
Q1 25
-5.66×
-5.66×
Q4 24
4.36×
Q3 24
0.39×
4.72×
Q2 24
1.96×
Q1 24
-5.35×
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KRO
KRO

Segment breakdown not available.

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons